Often, cancerous cells produce aberrant DNA molecules which are difficult to detect by normal genome sequencing techniques. Fluorescent In-Situ Hybridization (FISH) is a highly sensitive and specific detection method for identifying these cytogenetic changes. ApoCell develops state-of-the-art FISH assays to detect abnormalities in both hematological and solid organ tumors.

 

Contact Us

For more information on how our FISH expertise can help accelerate your drug development timeline

Contact Us

FISH taking place

Cytogenetic analysis of CTCs often provides information regarding diagnosis, prognosis and therapeutic surveillance of cancer patients.

We have developed DNA FISH assays to cytogenetically analyze CTCs after enrichment from patient whole blood. Isolated cells are first immunophenotyped to identify CTCs and then CTCs are relocated after target-specific FISH analysis has been performed.

  • FISH in CTCs, CECs, FFPE, frozen tissue, and bone
  • Detect cellular genetic aberrations: multiploidy, translocations, amplifications or deletions
  • Custom FISH probe design services
  • Commercially available FISH assays
  • Proprietary disease-specific FISH panels

The markers below are commonly utilized FISH targets; please visit our Test Menu for a more thorough listing.

HER2PTEN
c-MetEGFR
ARTMPRSS-ERG
EML4-ALKIGF1R
1

ISH

In addition to examining changes in DNA by FISH, ApoCell is also able to query modifications to RNA targets using ACD’s RNAscope ISH assays and technology. Commercially available or custom RNA ISH targets are available for incorporation into one of our integrated workflows.

Request for Proposal

Contact us to request a custom proposal to utilize ApoCell's service offerings and technologies to help meet your clinical and research needs.

Contact Us

Circulating Tumor Cells

ApoCell is a pioneer in capturing and analyzing circulating tumor cells (CTCs) from patient blood to monitor the pharmacodynamic effects of investigational therapies in clinical trials.

Learn More